The senolytic combination of dasatinib and quercetin (D+Q) administered long-term to naturally aged mice reduced senescence biomarkers p16, p21, and SA-β-gal, restored the anti-aging protein Klotho, attenuated renal fibrosis and inflammation, and reactivated PPARα signaling to improve fatty acid oxidation. Single-cell transcriptomics demonstrated reversal of transcriptional aging signatures across multiple renal cell types, while cell-cell communication analysis showed normalization of a hyperconnected intercellular signaling network characteristic of aged kidneys.
This is among the most mechanistically comprehensive studies to date examining D+Q senolytics in kidney aging, integrating proteomics, single-cell RNA sequencing, and intercellular communication mapping in a single model. The PPARα-lipid metabolism axis is a particularly notable finding — lipotoxicity in renal tubular cells is increasingly recognized as a fibrosis accelerant, and pharmacological rescue of that pathway adds real mechanistic specificity beyond simple senescent cell clearance. The Klotho restoration is equally significant, given Klotho's established role as a longevity-associated circulating factor that declines sharply with age and CKD progression.
Critical limitations must be acknowledged: this is an animal study in naturally aged mice, and D+Q pharmacokinetics, dosing intervals, and tissue distribution differ substantially in humans. D+Q also carries meaningful clinical toxicity considerations — dasatinib is a tyrosine kinase inhibitor with cardiovascular and immunosuppressive risks. While confirmatory of prior D+Q findings, the single-cell resolution elevates this work above incremental, making it a meaningful mechanistic advance for the senotherapy field.
